Literature DB >> 25514909

Role of adipokines and cytokines in non-alcoholic fatty liver disease.

Ludovico Abenavoli, Valentina Peta1.   

Abstract

One of the most common hepatic manifestations of the metabolic syndrome is non-alcoholic fatty liver disease (NAFLD). This disease varies from simple steatosis to cirrhosis and hepatocellular carcinoma. Different molecules secreted from adipose tissue such as adiponectin, leptin, resistin and visfatin and pro-inflammatory cytokines such as tumour necrosis factor-α, and interleukins, can be involved in the pathogenesis of NAFLD. In this review we describe the role of these adipokines and cytokines in the pathogenesis of NAFLD. We comment on their potential use as non-invasive biomarkers of steatosis and fibrosis, and their potential therapeutic role.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25514909     DOI: 10.2174/1574887109666141216102458

Source DB:  PubMed          Journal:  Rev Recent Clin Trials        ISSN: 1574-8871


  29 in total

1.  Association of Adiponectin gene polymorphisms and nonalcoholic fatty liver disease.

Authors:  Hong-Jue Li; Chang-Ping Li; Chao Zhang; Xiao-Lin Zhong; Lei Shi
Journal:  Int J Clin Exp Med       Date:  2015-09-15

2.  Resistin Levels in Non-alcoholic Fatty Liver Disease Pathogenesis.

Authors:  Carmela Colica; Ludovico Abenavoli
Journal:  J Transl Int Med       Date:  2018-03-28

3.  Liver metabolic disruption induced after a single exposure to PCB126 in rats.

Authors:  Natalie A Chapados; Marie-Pier Boucher
Journal:  Environ Sci Pollut Res Int       Date:  2016-10-31       Impact factor: 4.223

4.  Adipokine Levels Versus Hepatic Histopathology in Bariatric Surgery Patients.

Authors:  Rafael Bergesch D'Incao; Cristiane Valle Tovo; Vanessa Suñé Mattevi; Diego Olschowsky Borges; Jane Maria Ulbrich; Gabriela Perdomo Coral; Mauricio Jacques Ramos; Nelson Guardiola Meinhardt
Journal:  Obes Surg       Date:  2017-08       Impact factor: 4.129

5.  Adiponectin serum level changes and its dynamic relationship with hepatitis C during viral clearance.

Authors:  Ludovico Abenavoli; Luigi Boccuto
Journal:  Virulence       Date:  2017-04-04       Impact factor: 5.882

Review 6.  Nonalcoholic Fatty Liver Disease: An Update on the Diagnosis.

Authors:  Jia-Zhen Zhang; Jing-Jing Cai; Yao Yu; Zhi-Gang She; Hongliang Li
Journal:  Gene Expr       Date:  2019-04-22

Review 7.  Extrahepatic organs in the development of non-alcoholic fatty liver disease in liver transplant patients.

Authors:  Renyi Su; Xuyong Wei; Qiang Wei; Di Lu; Zuyuan Lin; Shuo Wang; Chuxiao Shao; Xiao Xu
Journal:  Hepatobiliary Surg Nutr       Date:  2022-06       Impact factor: 8.265

Review 8.  Metabolic aspects of adult patients with nonalcoholic fatty liver disease.

Authors:  Ludovico Abenavoli; Natasa Milic; Laura Di Renzo; Tomislav Preveden; Milica Medić-Stojanoska; Antonino De Lorenzo
Journal:  World J Gastroenterol       Date:  2016-08-21       Impact factor: 5.742

9.  Relevance of low testosterone to non-alcoholic fatty liver disease.

Authors:  Avni Mody; Donna White; Fasiha Kanwal; Jose M Garcia
Journal:  Cardiovasc Endocrinol       Date:  2015-09-01

10.  Apigenin Ameliorates Dyslipidemia, Hepatic Steatosis and Insulin Resistance by Modulating Metabolic and Transcriptional Profiles in the Liver of High-Fat Diet-Induced Obese Mice.

Authors:  Un Ju Jung; Yun-Young Cho; Myung-Sook Choi
Journal:  Nutrients       Date:  2016-05-19       Impact factor: 5.717

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.